Pharma BD Deal Intelligence
Made Zimmer the world's #1 pure-play orthopedics company, but the acquired Sulzer/Centerpulse implant litigation legacy and the follow-on Durom Cup crisis cost hundreds of millions and consumed a decade-plus of management attention.
Full analysis, sources & comparables →Zimmer announced a $3.04 billion bid for Centerpulse, topping Smith & Nephew's earlier $2.35 billion offer and positioning Zimmer to acquire Europe's largest…
Shares representing approximately 86.7% of Centerpulse's share capital have been tendered. Chairman/CEO Max Link: 'As a significant part of the leading…
Bank of America's Bob Hopkins later credited Zimmer management with executing the Centerpulse merger 'flawlessly,' completing 3,000+ integration milestones…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Counter-bid to Smith & Nephew's March 2003 $2.35B offer. Zimmer ultimately won at ~$3.2B; closed October 2003. Made Zimmer Europe's #1 orthopedic device co. Sources: EU Commission ip_03_763, Healio, Zimmer Holdings HBS case.
Made Zimmer the world's #1 pure-play orthopedics company, but the acquired Sulzer/Centerpulse implant litigation legacy and the follow-on Durom Cup crisis cost hundreds of millions and consumed a decade-plus of management attention.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Zimmer Holdings Inc. / Centerpulse AG (this deal) | 2003 | $3.2B | 60 |
| Zimmer Holdings Inc. / Biomet Inc. | 2014 | $13.3B | 63 |
| Zimmer Holdings Inc. / Paragon 28, Inc. | 2025 | $1.1B | — |
| Eli Lilly and Company / Applied Molecular Evolution Inc. | 2003 | $400M | 88 |
| Takeda Pharmaceutical Company Ltd. / Millennium Pharmaceuticals | 2003 | $8.8B | 82 |
| Genzyme Corporation / SangStat Medical Corporation | 2003 | $600M | 78 |
| Takeda Pharmaceutical Company Ltd. / Ariad Pharmaceuticals | 2003 | $5.2B | 77 |
← Browse all deals · How we score deals
More: 2003 deals · Zimmer Holdings Inc. deals